Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Bicycle Therapeutics (BCYC) over the last 7 years, with Q1 2025 value amounting to $133000.0.

  • Bicycle Therapeutics' Change in Receivables changed N/A to $133000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $170000.0, marking a year-over-year change of. This contributed to the annual value of -$2.5 million for FY2023, which is 25124.92% down from last year.
  • As of Q1 2025, Bicycle Therapeutics' Change in Receivables stood at $133000.0.
  • Over the past 5 years, Bicycle Therapeutics' Change in Receivables peaked at $49.9 million during Q3 2023, and registered a low of -$49.8 million during Q2 2023.
  • For the 4-year period, Bicycle Therapeutics' Change in Receivables averaged around -$477363.6, with its median value being -$991000.0 (2022).
  • The largest annual percentage gain for Bicycle Therapeutics' Change in Receivables in the last 5 years was 61450.38% (2023), contrasted with its biggest fall of 58214.18% (2023).
  • Over the past 4 years, Bicycle Therapeutics' Change in Receivables (Quarter) stood at $1.0 million in 2021, then skyrocketed by 98.7% to $2.0 million in 2022, then surged by 2407.59% to $49.9 million in 2023, then crashed by 99.73% to $133000.0 in 2025.
  • Its Change in Receivables was $133000.0 in Q1 2025, compared to $49.9 million in Q3 2023 and -$49.8 million in Q2 2023.